Bafna Pharmaceuticals Limited (BAFNAPH) Share Price
NSE · Healthcare · Drug Manufacturers - Specialty & Generic · ISIN INE878I01022
Key metrics
- Market Cap
- ₹574 Cr
- P/E Ratio
- 73.92
- EPS
- 3.28
- Book Value
- 40.64
- P/B Ratio
- 5.97
- ROE
- 11.54%
- ROCE
- 7.39%
- Debt / Equity
- 0.39
- Net Margin
- 7.37%
- Revenue Growth
- 3.26%
- Profit Growth
- 167.3%
- Dividend Yield
- —
- 52W High
- ₹290.70
- 52W Low
- ₹91.20
- Market Cap Band
- small cap
- Face Value
- —
Ratios computed from the annual results period ending 2026-03-31.
About Bafna Pharmaceuticals Limited
Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. The company offers its products in various dosage forms, including tablets, capsules, and solid orals. It provides various products for cardiovascular and hypertension, potent oncology, anti-infectives, central nervous system, and diabetic related diseases, as well as provision of contract research and manufacturing services. It also exports its products to Europe, the United Kingdom, Australia, Sri Lanka, Africa, Philippines, Tanzania, and Nigeria. Bafna Pharmaceuticals Limited was founded in 1981 and is based in Chennai, India. The company operates as a subsidiary of SRJR Lifesciences LLP.
- Headquarters
- Chennai, India
- Promoter Holding
- 89.7%
The full Bafna Pharmaceuticals Limited analysis
Create a free account to open the complete BAFNAPH deep-dive — fourteen tabs of fundamental, technical, institutional and ownership data.
- 10-year financialsIncome statement, balance sheet and cash flow, year by year.
- Valuation & fair valueFair-value estimates, quality scores and a value grade.
- Charts & technicalsCandlestick charts, RSI, MACD, Supertrend and detected patterns.
- Shareholding historyPromoter, FII, DII and public holdings across every quarter.
- Ace investor holdingsWhich well-known investors hold it, and how their stake changed.
- Deals & insider tradesBulk and block deals, insider transactions and mutual-fund holdings.